ER-PR Her-2 testing helps assess breast cancer hormone receptors (ER, PR) and Her-2 protein levels to determine the best treatment pathway. Diagnopein ensures accurate, fast, and reliable cancer ma
The ER-PR Her-2 test is a crucial diagnostic tool used to evaluate specific hormone receptors and protein expressions in breast cancer tissue. This test helps doctors understand how the cancer cells are growing and which treatment would be most effective.
ER (Estrogen Receptor), PR (Progesterone Receptor), and Her-2 (Human Epidermal Growth Factor Receptor 2) are essential biomarkers that indicate the molecular characteristics of breast cancer. By assessing these markers, healthcare providers can personalize therapy—making cancer treatment more accurate and successful.
Breast cancer growth often depends on hormones like estrogen and progesterone. The ER-PR Her-2 test identifies whether cancer cells have receptors for these hormones or excess Her-2 proteins. This insight not only aids in diagnosis but also ensures that the treatment aligns with the tumor biology, improving patient outcomes.
ER-PR Her-2 testing plays a significant role in breast cancer management and prognosis. It allows oncologists to classify breast cancer into hormone receptor-positive, Her-2 positive, or triple-negative types.
Understanding this classification helps in:
Determining whether hormone therapy or targeted therapy will be effective
Predicting how aggressive the cancer might be
Choosing precise treatment strategies for better survival outcomes
Patients with ER-positive or PR-positive results are most likely to benefit from hormone therapy, while those with Her-2 positive cancers often respond well to targeted drugs like trastuzumab. Hence, this test is not just diagnostic—it guides personalized, evidence-based treatment.
The ER-PR Her-2 test offers several benefits for both patients and healthcare professionals:
Accurate Diagnosis: Enables better understanding of tumor behavior and growth mechanisms.
Personalized Treatment: Helps in tailoring therapy plans suited to individual tumor types.
Improved Prognosis: Provides valuable insights for predicting treatment response and recurrence risk.
Cost-Effective Care: Avoids unnecessary treatments, focusing only on what truly benefits the patient.
Better Survival Rate: Enhances treatment precision, leading to improved recovery rates.
With Diagnopein’s advanced diagnostic technology, the ER-PR Her-2 testing process ensures a thorough assessment of cancer markers for precise medical decisions.
The ER-PR Her-2 test is performed on a small tissue sample obtained through a biopsy or surgery. The procedure is usually conducted using Immunohistochemistry (IHC) or Fluorescence In Situ Hybridization (FISH) techniques, depending on the clinical requirements.
Key Parameters Evaluated:
ER (Estrogen Receptor): Measures the presence of estrogen receptors in the tumor cells.
PR (Progesterone Receptor): Detects progesterone receptors, indicating hormone sensitivity.
Her-2 (Human Epidermal Growth Factor Receptor 2): Determines if the cancer overexpresses the Her-2 protein, which influences tumor growth and treatment response.
Once the tissue is processed in the laboratory, a detailed ER-PR Her-2 report is provided, explaining the receptor status and scores. Based on these findings, oncologists design the treatment plan using hormone therapy, chemotherapy, or targeted therapy as required.
Advanced laboratory infrastructure using IHC and molecular techniques
Team of experienced pathologists and oncopathology specialists
Reliable and fast turnaround time for reports
Transparent pricing with patient-centric services
Accurate results for precise cancer treatment planning
Biopsies are generally safe but may carry minor risks such as bleeding, infection, or discomfort at the site.
Yes, the test is standard for newly diagnosed breast cancer patients to inform treatment strategies and is typically performed on tumor tissue obtained during a biopsy.
The test is performed on a tumor sample obtained through a biopsy. The sample is analyzed in a lab using techniques like immunohistochemistry (IHC) for ER and PR and fluorescence in situ hybridization (FISH) for Her2.
The test provides critical information for personalized treatment plans, predicting how well a patient may respond to certain therapies, and offering prognostic information about the cancer's aggressiveness.
